Very simple questions ..
--How many in lenzilumab studies were on a ventilators ,
--How many in your studies were on ECMO
--How many were admitted to your study with any secondary bacterial , viral or fungi infection.
--How many times during lenzilumab studied CEO " picked " as he said , without penalty to see active study resuts , and then change the primary endpoint ..
How many EIND you did with lenzilumab , How many dying or on a ventilators or on ECMO requested your drug.
Leronlimab did about 100 , all requested by a patients or a family of a patients.
I am done for now.